With the acquisition of Pharmatek Laboratories, Catalent now offers spray drying as part of its bioavailability toolkit, complementing its comprehensive suite of development and formulation solutions.
From early phase development through to clinical manufacturing scale, spray drying can assist in overcoming formulation and development challenges.
With the acquisition of Pharmatek Laboratories, Catalent now offers spray drying as part of its bioavailability toolkit, complementing its comprehensive suite of development and formulation solutions. Additionally, the expansion of development and clinical manufacturing capabilities strengthens Catalent’s ability to partner with customers earlier in pre-clinical development.
Pharmatek’s San Diego facility expands Catalent’s global network of clinical and commercial manufacturing supply facilities, which integrates drug development and delivery for both oral and injectable dose forms. The site has the capacity to provide rapid development from prototype to optimal final dose form, with integrated characterization, analytical, pre-formulation, formulation, process development, and cGMP manufacturing. The facility has over 18,000 square feet of laboratory, manufacturing and support space dedicated to development and manufacturing of highly-potent compounds.
Spray drying technology will now be incorporated into OptiForm® Solution Suite, Catalent’s award-winning screening platform, to assess optimal formulation pathways for the oral delivery potential of both small and large molecule drugs.